c-Met inhibitors

被引：18

作者：

Mughal, Anum ^{[1
]}

Aslam, Hafiz Muhammad ^{[1
]}

Sheikh, Asfandyar ^{[1
,2
]}

Khan, Agha Muhammad Hammad ^{[3
]}

Saleem, Shafaq ^{[1
]}

机构：

[1] Dow Univ Hlth Sci, Dow Med Coll, Karachi, Pakistan

[2] Pakistan Res Evolut Students Soc, Karachi, Pakistan

[3] Dow Univ Hlth Sci, Sindh Med Coll, Karachi, Pakistan

来源：

INFECTIOUS AGENTS AND CANCER | 2013年 / 8卷

关键词：

c-Met; Tyrosine kinase; Cancer; HEPATOCYTE GROWTH-FACTOR; FACTOR-RECEPTOR; SOMATIC MUTATIONS; KINASE INHIBITORS; ONCOGENE; IDENTIFICATION; PROTOONCOGENE; DISCOVERY; DOMAIN; GENE;

D O I：

10.1186/1750-9378-8-13

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

c-Met is a receptor tyrosine kinase that encodes protein such as hepatocyte growth factor receptor (HGFR). Inappropriate activity of c-Met can cause wide variety of carcinomas. c-Met inhibitor are relatively new class of small molecules that inhibit the enzymatic activity of c-Met tyrosine kinase. Met inhibitors divided into two main classes: class I (SU-11274-like) and class II (AM7-like). The use of c-Met inhibitors with other therapeutic agents could be crucial for overcoming potential resistance as well as for improving overall clinical benefit. Met pathway inhibitors might be used in combination with other treatments, including chemo-, radio-or immunotherapy

引用

页数：2

共 50 条

[41] Discovery and optimization of a potent and selective triazolopyridinone series of c-Met inhibitors
Bode, Christiane M.
Boezio, Alessandro A.
Albrecht, Brian K.
Bellon, Steven F.
Berry, Loren
Broome, Martin A.
Choquette, Deborah
Dussault, Isabelle
Lewis, Richard T.
Lin, Min-Hwa Jasmine
Rex, Karen
Whittington, Douglas A.
Yang, Yajing
Harmange, Jean-Christophe
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2012, 22 (12) : 4089 - 4093
[42] Discovery of novel inhibitors for c-Met by virtual screening and pharmacophore analysis
Chen, Calvin Yu-Chian
JOURNAL OF THE CHINESE INSTITUTE OF CHEMICAL ENGINEERS, 2008, 39 (06): : 617 - 624
[43] c-MET kinase inhibitors: a patent review (2011-2013)
Zhu, Kongkai
Kong, Xiangqian
Zhao, Dan
Liang, Zhongjie
Luo, Cheng
EXPERT OPINION ON THERAPEUTIC PATENTS, 2014, 24 (02) : 217 - 230
[44] Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors
Boezio, Alessandro A.
Berry, Loren
Albrecht, Brian K.
Bauer, David
Bellon, Steven F.
Bode, Christiane
Chen, April
Choquette, Deborah
Dussault, Isabelle
Hirai, Satoko
Kaplan-Lefko, Paula
Larrow, Jay F.
Lin, Min-Hwa Jasmine
Lohman, Julia
Potashman, Michele H.
Rex, Karen
Santostefano, Michael
Shah, Kavita
Shimanovich, Roman
Springer, Stephanie K.
Teffera, Yohannes
Yang, Yajing
Zhang, Yihong
Harmange, Jean-Christophe
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2009, 19 (22) : 6307 - 6312
[45] The role of c-MET inhibitors in advanced hepatocellular carcinoma: now and future
Woo, Hyun Young
Heo, Jeong
ANNALS OF TRANSLATIONAL MEDICINE, 2020, 8 (23)
[46] Role of the HGF/c-MET tyrosine kinase inhibitors in metastasic melanoma
Lucia Demkova
Lucia Kucerova
Molecular Cancer, 17
[47] Biochemical characterization of novel EGFR and c-Met single and dual inhibitors
Gyulavari, P.
Szantai-Kis, C.
Orfi, L.
Pato, J.
Waczek, F.
Szabadkai, I.
Breza, N.
Keri, G.
Vantus, T.
FEBS JOURNAL, 2010, 277 : 121 - 121
[48] Mechanism of resistance to c-Met tyrosine kinase inhibitors in human melanoma
Etnyre, Deven
Fong, Jason
Bertram, Ceyda
Puri, Neelu
CANCER RESEARCH, 2012, 72
[49] Discovery, optimization and biological evaluation for novel c-Met kinase inhibitors
Yuan, Haoliang
Liu, Qiufeng
Zhang, Li
Hu, Shihe
Chen, Tiantian
Li, Huifang
Chen, Yadong
Xu, Yechun
Lu, Tao
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2018, 143 : 491 - 502
[50] O-Linked Triazolotriazines: Potent and Selective c-Met Inhibitors
Chen, Fang
Wang, Ying
Ai, Jing
Zhan, Zhengsheng
Lv, Yongcong
Liang, Zhongjie
Luo, Cheng
Mei, Desheng
Geng, Meiyu
Duan, Wenhu
CHEMMEDCHEM, 2012, 7 (07) : 1276 - 1285

← 1 2 3 4 5 →